Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide plus temozolomide with radiotherapy in newly diagnosed glioblastoma
2004-004849-18Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2005
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cilengitide in glioblastoma (GBM), sponsored by Merck KGaA. Primary endpoint: 6-month progression-free survival rate. Started Jul 2005; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2004-004849-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004849-18.